Table 1.
Groups for the ECG Analysis | Main Study Groups | Number of Subjects | MVA Dose | Route* | Day 0 | Day 28 (Week 4) | Day 112 (Week 16) |
---|---|---|---|---|---|---|---|
1 | A | 15 | 2×107 | SC | MVA | MVA‡ | Dryvax®† |
B | 15 | 5×107 | SC | MVA | MVA‡ | Dryvax®† | |
C | 15 | 1×108 | SC | MVA | MVA‡ | Dryvax®† | |
F | 15 | 1×108 | IM | MVA | MVA‡ | Dryvax®† | |
2 | D | 15 | N/A | SC | Placebo** | Placebo** | Dryvax®† |
3 | E | 15 | 1×108 | SC | MVA | MVA‡ | Placebo** |
SC=subcutaneous, IM=intramuscular
1 × 108 plaque forming units (pfu)
Tissue culture infective dose 50 (TCID50)
The placebo is sterile normal saline